New immune cell therapy for hard-to-treat autoimmune diseases

Plain-English translation of NCT06794008 on ClinicalTrials.gov ↗ · Source last updated April 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new treatment called for people with autoimmune diseases that haven't improved with standard medicines. The treatment uses specially engineered immune cells from your own body that are designed to target and calm down the overactive immune response causing your disease. Researchers want to see if this medication can help patients get better when other treatments have failed.

Many people with serious autoimmune diseases like lupus, vasculitis, and scleroderma don't improve even after trying multiple standard treatments. This trial exists to explore whether this new immune cell therapy could offer hope to patients who have run out of other options.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old and weigh at least 45 kilograms
you have been formally diagnosed with one of the autoimmune diseases being studied (lupus, vasculitis, scleroderma, Sjögren's syndrome, inflammatory muscle disease, Behçet's disease, or related conditions)
your disease has not improved despite trying multiple treatments including high-dose steroids, immunosuppressive drugs, and biologic therapies
you have been on stable doses of your current medications for at least 4 weeks before starting the trial
you are willing to use effective birth control throughout the study and agree not to become pregnant or father a child during the trial

You likely don't qualify if…

you have active infection or recent serious infection
you are currently taking certain medications that would interfere with the treatment
you are pregnant, breastfeeding, or unwilling to use reliable contraception
you have certain types of cancer or cancer history within a specified timeframe
you have severe organ damage or other serious medical conditions that would make the treatment unsafe

What participation looks like

If you join this trial, you will receive the new immune cell therapy as a single intravenous infusion over one day at the hospital. Before the infusion, you'll receive a brief preparation regimen to get your body ready. After receiving the treatment, you'll be closely monitored with follow-up visits to track how well the therapy is working and to watch for any side effects. The study will measure improvements in your disease symptoms and blood work over time.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Trial locations(1 site)

China

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing Municipality